Arkolith/Insider Trading/EIGR/Form 4

Dietz Thomas John

DirectorEiger BioPharmaceuticals, Inc. (EIGR) · full profile →Form 4 · filed Jan 25, 2023
Net Buying
Open-Market Buys
$72K
Open-Market Sells
$0
Net Open-Market Flow
$72K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 23, 2023Buy(P)50K$1.43$72K50K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001567619-23-001284) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML